dc.creatorFernando Florenzano,
dc.date.accessioned2019-03-11T13:03:07Z
dc.date.available2019-03-11T13:03:07Z
dc.date.created2019-03-11T13:03:07Z
dc.date.issued2011
dc.identifierRevista Medica de Chile, Volumen 139, Issue 11, 2018, Pages 1393-1395
dc.identifier00349887
dc.identifier07176163
dc.identifier10.4067/S0034-98872011001100001
dc.identifierhttps://repositorio.uchile.cl/handle/2250/165471
dc.description.abstractDuring recent decades, acute myocardial infarction short-term mortality has decreased to one digit levels, in the United States. Data from Chilean registries give figures around 11% for patients receiving thrombolysis, and 5 to 6 % for patients treated with angioplasty. The decrease in mortality in Chile is related to the implementation of the AUGE program at a national level, initiative than gives patients the opportunity to receive at least thrombolytic therapy as well as a standardized and rapid diagnosis and treatment for this condition. There is a lack of Outcome Research studies in Chile, that would guide public health decisions such as the use of fibrin-specific agents for early presentation and high risk cases, and a rational system providing better access to primary angioplasty.
dc.languageen
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/3.0/cl/
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 Chile
dc.sourceRevista Medica de Chile
dc.subjectMortality
dc.subjectMyocardial infarction
dc.subjectMyocardial reperfusion
dc.subjectThrombolytic therapy
dc.titleAcute myocardial infarction mortality in Chile. Thrombolysis or angioplasty Mortalidad por infarto del miocardio en Chile. Trombolíticos o angioplastía
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución